Blood Cancer Talks

In this episode, we delve into the latest data on bispecific antibodies in multiple myeloma with Dr. Ajai Chari. Here are the key studies discussed:

1. Teclistamab (MajesTEC-1 trial):

2. Correlative analysis from MajesTEC-1 trial:

3.  Talquetamab (MonumenTAL-1 trial):

4. Phase 1 trial of fixed-duration cevostamab

5. Phase 1 trial of ABBV-383:

6. Paper summarizing infections with different bispecific antibodies in myeloma:

What is Blood Cancer Talks?

This is a podcast on latest advances in the understanding and management of blood cancers. Here, we will bring a wide range of experts within hematologic malignancies to discuss various topics in depth.
Host: Raj Chakraborty, MD from Columbia University, New York, Ashwin Kishtagari, MD, from Vanderbilt University, Nashville, and Edward Cliff, MD, from Harvard University, Boston
Tweet your suggestions and feedback to @rajshekharucms @AshKishtagari @Eddie_Cliff @BloodCancerTalk